Mendelian

Executive Summary

Mendelian is a UK-based digital health company founded in 2015 with a mission to end the diagnostic odyssey for rare disease patients. Its core product, MendelScan, is an expert-guided platform that scans electronic health records in primary care settings to flag undiagnosed patients displaying clinical features suggestive of rare conditions. By leveraging existing data, the software aims to reduce the average 4-8 year delay in rare disease diagnosis, enabling earlier intervention and improved patient outcomes. The company targets a significant unmet need: approximately 300 million people worldwide live with a rare disease, yet many remain undiagnosed due to lack of awareness and fragmented healthcare data. Mendelian operates in the growing digital diagnostics market, which is driven by increasing adoption of EHR systems and AI-assisted clinical decision support. While the company has not disclosed funding or revenue details, its focus on primary care integration positions it well for scalability. The platform has the potential to be integrated into national health systems like the NHS, which is actively seeking solutions to improve rare disease diagnosis. However, as a private company with limited public traction, Mendelian faces challenges in demonstrating clinical utility and securing commercial partnerships. Success will depend on validation studies, regulatory clearances, and strategic collaborations to expand beyond the UK.

Upcoming Catalysts (preview)

• Q3 2026NHS Pilot Program Partnership70% success
• Q4 2026Expansion of MendelScan to Additional Rare Disease Indications50% success
• Q2 2026Series A Funding Round60% success